MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Cost of Revenue 2011-2026 | ONVO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 K | - | - | - | 300 K | 500 K | 1.03 M | 956 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 M | 5 K | 558 K |
Quarterly Cost of Revenue Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2 K | 1 K | 2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 K | 300 K | 300 K | 100 K | 100 K | 100 K | 100 K | - | 200 K | 300 K | 300 K | - | 212 K | 773 K | 561 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 773 K | 1 K | 210 K |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
180 M | $ 9.26 | 1.09 % | $ 617 M |  USA |
 |
DarioHealth Corp.
DRIO
|
9.69 M | $ 8.45 | 9.74 % | $ 33.7 M |  Israel |
 |
DexCom
DXCM
|
1.86 B | $ 66.09 | -1.12 % | $ 25.8 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 103.08 | 3.09 % | $ 8.5 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.64 B | $ 573.29 | -0.42 % | $ 46.1 B | USA |
 |
Illumina
ILMN
|
1.51 B | $ 124.4 | -1.43 % | $ 19.8 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.62 | -1.28 % | $ 428 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Natera
NTRA
|
158 M | $ 196.15 | -0.62 % | $ 19.3 B | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
495 M | $ 1.17 | -1.68 % | $ 812 M | USA |
 |
Pacific Biosciences of California
PACB
|
114 M | $ 1.35 | -2.88 % | $ 405 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 4.59 | 22.4 % | $ 2.46 M | USA |
 |
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Personalis
PSNL
|
57.8 M | $ 7.32 | -4.94 % | $ 434 M | USA |
 |
Interpace Biosciences
IDXG
|
17 M | $ 1.73 | 2.37 % | $ 7.59 M | USA |
 |
RadNet
RDNT
|
1 B | $ 59.41 | -2.06 % | $ 4.47 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 6.56 | -2.96 % | $ 274 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 268.38 | 0.89 % | $ 22.3 B | USA |
 |
NeoGenomics
NEO
|
413 M | $ 7.76 | -0.13 % | $ 994 M | USA |
 |
Soleno Therapeutics
SLNO
|
2.7 M | $ 31.83 | -0.03 % | $ 1.62 B | USA |
 |
Psychemedics Corporation
PMD
|
13.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
9.18 M | $ 27.2 | -0.15 % | $ 35.3 M | USA |